BMS-351

• UNSPSC Description:

  BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC50 values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1,respectively. BMS-351 can be used for the study of castration-resistant prostate cancer[1].

• Target Antigen:

  Cytochrome P450

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bms-351.html

• Smiles:

  FC(F)(CN1C=NC2=C1C=CC=C2C3=C(C)C=CN=C3)F

• Molecular Weight:

  291.27

• References & Citations:

  [1]Huang A, et al. Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer. ACS Med Chem Lett. 2015;7(1):40-45. Published 2015 Dec 2.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1370001-71-0